Back to Search
Start Over
Heparin: An old drug for new clinical applications.
- Source :
-
Carbohydrate Polymers . Nov2022, Vol. 295, pN.PAG-N.PAG. 1p. - Publication Year :
- 2022
-
Abstract
- Heparin, an old but first-line anticoagulant, has been used over a century. It is a heterogeneous, linear, highly sulfated, anionic glycosaminoglycan with a broad distribution in relative molecular weight and charge density. These structural properties allow heparin to selectively interact with multiple proteins, leading to heparin's various pharmacological functions, such as anticoagulant, anti-viral, anti-tumor and anti-inflammatory activities. Clinical data suggest that unfractionated heparin or low molecule weight heparin could decrease mortality in COVID-19 patients with sepsis-induced hypercoagulation through the anticoagulant, anti-viral and anti-inflammatory activities of these drugs. Thus, the non-anticoagulant activity of heparin has again aroused attention. This review highlights recent advances in the preparation of heparin-derived drugs and clinical research on its non-anticoagulant properties over the past decade, to further the development and utilization of these important drugs. [Display omitted] [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01448617
- Volume :
- 295
- Database :
- Academic Search Index
- Journal :
- Carbohydrate Polymers
- Publication Type :
- Academic Journal
- Accession number :
- 158607535
- Full Text :
- https://doi.org/10.1016/j.carbpol.2022.119818